Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TG4010 + cisplatin + vinorelbine
- Development stage
- Discontinued
- Lead developer
- Transgene
- Modality
- Vaccines & Immunotherapeutics, Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
TG4010 + cisplatin + vinorelbine is a combination therapy for non-small cell lung cancer (NSCLC). TG4010 is a therapeutic cancer vaccine based on a modified vaccinia Ankara (MVA) virus that expresses the MUC1 tumor-associated antigen and interleukin-2 (IL-2). This combination has been studied in clinical trials for advanced NSCLC, where TG4010 is administered subcutaneously at a dose of 10^8 pfu weekly for six weeks and then every three weeks, alongside standard chemotherapy consisting of cisplatin and vinorelbine.
02
Targets
DNAMUC1 (Mucin-1 Antigen)TUBB (Tubulin (alpha and beta subunits))IL-2 (Interleukin 2)
Beyond the preview
Go deeper on TG4010 + cisplatin + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TG4010 + cisplatin + vinorelbine.